Lymphoma CAR-T Therapy IM19 Approved in China for Relapsed or Refractory LBCL

On November 5, 2026, China’s National Medical Products Administration (NMPA) approved lymphoma CAR-T therapy IM19, developed by Imunopharm Technology, for adults with relapsed or refractory large B-cell lymphoma (r/r LBCL) after two or more prior…











